• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

FDA approves pembrolizumab for resectable head and neck cancer with PD-L1 expression

June 14, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
cancer cell
3
SHARES
6
VIEWS
Share on FacebookShare on Twitter


cancer cell
Credit: Unsplash/CC0 Public Domain

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

The FDA approval is based on data from the pivotal KEYNOTE-689 study, a randomized, open-label phase 3 clinical trial in which patients who received pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery. The study was led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

This new regimen represents a substantial change in workflow for head and neck cancer care, offering appropriate patients the option of receiving pembrolizumab before surgery for resectable locally advanced head and neck cancer.

“These findings represent a truly exciting time for our patients, as it is the first advance in this field in over two decades,” said Dr. Ravindra Uppaluri, the study’s overall principal investigator, director of Head and Neck Surgical Oncology at Dana-Farber and Brigham and Women’s Hospital, and Brigham and Women’s Hospital Endowed Chair in Otolaryngology.

“This is the first approval of a checkpoint inhibitor in the curative, perioperative setting and it represents a massive paradigm shift in how we manage surgically treated head and neck cancer going forward,” said Dr. Robert Haddad, chief of the Division of Head and Neck Oncology and the McGraw Chair in Head and Neck Oncology at Dana-Farber, professor of medicine at Harvard Medical School and the Dana-Farber Brigham Cancer Center principal investigator and member of the KEYNOTE-689 steering committee.

The KEYNOTE-689 trial randomized 714 patients with newly diagnosed stage 3 or stage 4A head and neck squamous cell cancer to receive either pembrolizumab before (called neoadjuvant), during and after (called adjuvant) standard of care or standard of care alone. The investigators also measured the presence of the target of pembrolizumab, PD-L1, in tumors to determine if higher scores of PD-L1 in tumors would affect response to treatment.

The study met its primary endpoint showing that patients who received pembrolizumab had longer event-free survival. Median event-free survival was 51.8 months with pembrolizumab and 30.4 without after a median of 38.3 months of follow-up. The team also observed significantly higher rates of major pathologic response, a substantial immune mediated tumor destruction seen in surgical resections.

The treatment was found to be safe with no new observed side effects. Further, patients taking pembrolizumab received surgery in a timely manner and were not delayed by immunotherapy-related side effects prior to surgery.

The data was previously presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting.

Provided by
Dana-Farber Cancer Institute


Citation:
FDA approves pembrolizumab for resectable head and neck cancer with PD-L1 expression (2025, June 14)
retrieved 14 June 2025
from https://medicalxpress.com/news/2025-06-fda-pembrolizumab-resectable-neck-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




cancer cell
Credit: Unsplash/CC0 Public Domain

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

The FDA approval is based on data from the pivotal KEYNOTE-689 study, a randomized, open-label phase 3 clinical trial in which patients who received pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery. The study was led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

This new regimen represents a substantial change in workflow for head and neck cancer care, offering appropriate patients the option of receiving pembrolizumab before surgery for resectable locally advanced head and neck cancer.

“These findings represent a truly exciting time for our patients, as it is the first advance in this field in over two decades,” said Dr. Ravindra Uppaluri, the study’s overall principal investigator, director of Head and Neck Surgical Oncology at Dana-Farber and Brigham and Women’s Hospital, and Brigham and Women’s Hospital Endowed Chair in Otolaryngology.

“This is the first approval of a checkpoint inhibitor in the curative, perioperative setting and it represents a massive paradigm shift in how we manage surgically treated head and neck cancer going forward,” said Dr. Robert Haddad, chief of the Division of Head and Neck Oncology and the McGraw Chair in Head and Neck Oncology at Dana-Farber, professor of medicine at Harvard Medical School and the Dana-Farber Brigham Cancer Center principal investigator and member of the KEYNOTE-689 steering committee.

The KEYNOTE-689 trial randomized 714 patients with newly diagnosed stage 3 or stage 4A head and neck squamous cell cancer to receive either pembrolizumab before (called neoadjuvant), during and after (called adjuvant) standard of care or standard of care alone. The investigators also measured the presence of the target of pembrolizumab, PD-L1, in tumors to determine if higher scores of PD-L1 in tumors would affect response to treatment.

The study met its primary endpoint showing that patients who received pembrolizumab had longer event-free survival. Median event-free survival was 51.8 months with pembrolizumab and 30.4 without after a median of 38.3 months of follow-up. The team also observed significantly higher rates of major pathologic response, a substantial immune mediated tumor destruction seen in surgical resections.

The treatment was found to be safe with no new observed side effects. Further, patients taking pembrolizumab received surgery in a timely manner and were not delayed by immunotherapy-related side effects prior to surgery.

The data was previously presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting.

Provided by
Dana-Farber Cancer Institute


Citation:
FDA approves pembrolizumab for resectable head and neck cancer with PD-L1 expression (2025, June 14)
retrieved 14 June 2025
from https://medicalxpress.com/news/2025-06-fda-pembrolizumab-resectable-neck-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Iran strikes back at Israel with missiles over Jerusalem and Tel Aviv

Next Post

Watch amazing footage of dolphins performing spectacular 3 metre-high aerial corkscrews – and learn how and why they do it

Related Posts

concussion

Why we need to take concussion and chronic traumatic encephalopathy more seriously

July 5, 2025
7

Journalists Assess Health Impacts of Trump’s Megabill, Who Will Feel Them, and When

July 5, 2025
7
Next Post

Watch amazing footage of dolphins performing spectacular 3 metre-high aerial corkscrews – and learn how and why they do it

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
At least 17 killed in deadly overnight Israeli attacks across Gaza

At least 17 killed in deadly overnight Israeli attacks across Gaza

July 6, 2025
Investment firm Azoria postpones Tesla ETF after Musk plans political party

Investment firm Azoria postpones Tesla ETF after Musk plans political party todayheadline

July 6, 2025
How to prepare your pets for when a hurricane makes it rain cats and dogs

How to prepare your pets for when a hurricane makes it rain cats and dogs

July 6, 2025
More residents evacuate quake-hit remote islands in Japan

More residents evacuate quake-hit remote islands in Japan

July 6, 2025

Recent News

At least 17 killed in deadly overnight Israeli attacks across Gaza

At least 17 killed in deadly overnight Israeli attacks across Gaza

July 6, 2025
5
Investment firm Azoria postpones Tesla ETF after Musk plans political party

Investment firm Azoria postpones Tesla ETF after Musk plans political party todayheadline

July 6, 2025
7
How to prepare your pets for when a hurricane makes it rain cats and dogs

How to prepare your pets for when a hurricane makes it rain cats and dogs

July 6, 2025
3
More residents evacuate quake-hit remote islands in Japan

More residents evacuate quake-hit remote islands in Japan

July 6, 2025
7

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

At least 17 killed in deadly overnight Israeli attacks across Gaza

At least 17 killed in deadly overnight Israeli attacks across Gaza

July 6, 2025
Investment firm Azoria postpones Tesla ETF after Musk plans political party

Investment firm Azoria postpones Tesla ETF after Musk plans political party todayheadline

July 6, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co